Orasure Technologies Inc (NASDAQ:OSUR) Institutional Investors Sentiment Index Crashed in 2017 Q4

May 18, 2018 - By Mary Hughes

Sentiment for Orasure Technologies Inc (NASDAQ:OSUR)

Orasure Technologies Inc (NASDAQ:OSUR) institutional sentiment decreased to 0.83 in Q4 2017. Its down -0.18, from 1.01 in 2017Q3. The ratio worsened, as 84 active investment managers increased or started new holdings, while 101 sold and decreased equity positions in Orasure Technologies Inc. The active investment managers in our partner’s database now possess: 53.79 million shares, down from 54.93 million shares in 2017Q3. Also, the number of active investment managers holding Orasure Technologies Inc in their top 10 holdings decreased from 4 to 3 for a decrease of 1. Sold All: 45 Reduced: 56 Increased: 50 New Position: 34.

OraSure Technologies, Inc., together with its subsidiaries, develops, makes, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company has market cap of $997.17 million. It operates in two divisions, OSUR and DNAG. It has a 32.02 P/E ratio. The firm also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

The stock increased 1.81% or $0.29 during the last trading session, reaching $16.33. About 352,732 shares traded. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 34.91% since May 18, 2017 and is uptrending. It has outperformed by 23.36% the S&P500.

Analysts await OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings on August, 1. They expect $0.04 EPS, down 55.56 % or $0.05 from last year’s $0.09 per share. OSUR’s profit will be $2.44 million for 102.06 P/E if the $0.04 EPS becomes a reality. After $-0.03 actual EPS reported by OraSure Technologies, Inc. for the previous quarter, Wall Street now forecasts -233.33 % EPS growth.

Domini Impact Investments Llc holds 11.7% of its portfolio in OraSure Technologies, Inc. for 30,262 shares. Daruma Capital Management Llc owns 3.04 million shares or 3.57% of their US portfolio. Moreover, Oberweis Asset Management Inc has 2.32% invested in the company for 526,610 shares. The Washington-based First Washington Corp has invested 2.26% in the stock. Pier Capital Llc, a Connecticut-based fund reported 360,089 shares.

Since January 1, 0001, it had 0 buys, and 2 sales for $778,707 activity.

OraSure Technologies, Inc. (NASDAQ:OSUR) Ratings Coverage

Ratings analysis reveals 67% of Orasure Technologies’s analysts are positive. Out of 3 Wall Street analysts rating Orasure Technologies, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $17.5 while the high is $24.0. The stock’s average target of $20.75 is 27.07% above today’s ($16.33) share price. OSUR was included in 4 notes of analysts from November 22, 2017. As per Friday, February 2, the company rating was maintained by Canaccord Genuity. The company was maintained on Tuesday, February 13 by Jefferies. Canaccord Genuity maintained the shares of OSUR in report on Wednesday, November 22 with “Buy” rating.

More notable recent OraSure Technologies, Inc. (NASDAQ:OSUR) news were published by: Globenewswire.com which released: “OraSure Announces 2018 First Quarter Financial Results” on May 02, 2018, also Globenewswire.com with their article: “OraSure Technologies Appoints New Chief Financial Officer” published on May 04, 2018, Streetinsider.com published: “OraSure Technologies (OSUR) Announces Roberto Cuca as New CFO” on May 04, 2018. More interesting news about OraSure Technologies, Inc. (NASDAQ:OSUR) were released by: Nasdaq.com and their article: “Market Trends Toward New Normal in Healthways, Global Net Lease, OraSure Technologies, Lions Gate …” published on April 24, 2018 as well as Globenewswire.com‘s news article titled: “OraSure Technologies to Present at the UBS Global Healthcare Conference” with publication date: May 14, 2018.

OraSure Technologies, Inc. (NASDAQ:OSUR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: